Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
Stock Information for Akari Therapeutics Plc
Loading
Please wait while we load your information from QuoteMedia.